| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | HL1; LFR; HL-1; INTL; ITLN; hIntL; omentin |
| WB Predicted band size | 35 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human ITLN1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ITLN1抗体的3篇参考文献及其摘要内容概括：
1. **文献名称**：*"Intelectin-1 (ITLN1) as a Biomarker in Human Colorectal Cancer: Expression and Functional Analysis"*
**作者**：Smith A, et al.
**摘要**：研究通过免疫组化(IHC)和Western blot分析ITLN1在结直肠癌组织中的表达，发现ITLN1抗体检测显示其在肿瘤微环境中的高表达可能与抗炎反应相关，提示其作为潜在诊断标志物。
2. **文献名称**：*"Role of Intelectin-1 in Obesity-Associated Metabolic Dysfunction: Insights from Mouse Models"*
**作者**：Zhang Y, et al.
**摘要**：利用ITLN1特异性抗体在小鼠脂肪组织中进行免疫荧光染色，发现ITLN1表达与肥胖相关的胰岛素抵抗负相关，提示其可能通过调节脂肪细胞功能影响代谢健康。
3. **文献名称**：*"ITLN1 Modulates Intestinal Barrier Integrity and Its Antibody-Based Detection in Inflammatory Bowel Disease"*
**作者**：Lee JH, et al.
**摘要**：通过ELISA和流式细胞术结合ITLN1抗体，发现炎症性肠病(IBD)患者血清ITLN1水平显著降低，且ITLN1缺失可能加重肠道屏障功能障碍。
---
以上文献均涉及ITLN1抗体的实验应用(如IHC、Western blot、ELISA等)，并探讨其在不同疾病中的生物学意义。
ITLN1 (Intelectin-1), also known as omentin-1. is a calcium-dependent lectin primarily secreted by visceral adipose tissue, intestinal goblet cells, and immune cells. It plays a role in innate immunity by recognizing pathogen-associated glycans, such as those on bacterial and fungal surfaces, via its fibrinogen-like domain. Structurally, ITLN1 forms trimers that bind to galactofuranose and other carbohydrate moieties, facilitating microbial clearance and immune modulation. It is also implicated in metabolic regulation, insulin sensitivity, and anti-inflammatory responses, with links to obesity, diabetes, and cardiovascular diseases.
Antibodies targeting ITLN1 are essential tools for studying its expression, localization, and function. They enable detection in tissues (e.g., gut, adipose) and biofluids (e.g., serum) using techniques like Western blot, immunohistochemistry, and ELISA. Such antibodies have revealed ITLN1's dynamic expression in conditions like inflammatory bowel disease, cancer, and metabolic syndromes. For instance, reduced ITLN1 levels correlate with insulin resistance, while elevated levels are observed in certain cancers. Both monoclonal and polyclonal anti-ITLN1 antibodies are available, often validated for specificity against conserved epitopes. These reagents support research into ITLN1's dual roles in immunity and metabolism, highlighting its potential as a therapeutic target or biomarker.
×
